Search studies

203167 Phase 2a in Psoriasis

ELU-4-EA431B-1

Psoriasis Phase 2a clinical study.

204869 Phase 2a/b in Ulcerative Colitis

ELU-4-907C53-1

204869 Phase 2a/b in Ulcerative Colitis

ABI-IBD

b4c2ea0c-c48e-11ec-9b1d-acde48001122

Patients with Crohn’s disease or ulcerative colitis diagnosis according to ECCO guidelines and who were prescribed adalimumab or infliximab (original product or biosimilar) were recruited from September 11, 2013 to February 15, 2016. Patients who were not naive to TNF inhibitor therapy or who were treated with corticoids more than 30 mg/day over the last 15 days were excluded.

ABI-MS

91f1a748-c48e-11ec-9b1d-acde48001122

Patients with MS or Clinically Isolated Syndrome (CIS) diagnosis according to McDonald criteria and who were prescribed IFN-beta-1a intramuscularly (IM), IFN-beta-1a subcutaneously (SC), or IFN-beta-1b SC (original product or biosimilar) were recruited from January 30, 2014 to January 22, 2016. Patients who were not naive to IFN-beta were excluded.

ABI-RA

b4c2e822-c48e-11ec-9b1d-acde48001122

Patients with RA diagnosis according to 2010 ACR/EULAR criteria and who were prescribed for the first time a BP among the TNF inhibitors adalimumab, infliximab (original product or biosimilar), etanercept, the anti-CD20 antibody rituximab, or the anti-IL6R antibody tocilizumab (administered SC or intravenously) as first-line or second-line therapy were recruited from March 3, 2014 to June 21, 2016. Patients who were not naive for the biotherapy they were given in the study were excluded.

AETIONOMY

dc9ac40c-147a-11eb-b51f-8c8590c45a21

Study phase: recruitment. For more details, see http://www.aetionomy.eu/content/dam/scai/AETIONOMY/Dokumente/Aetionomy_Newsletter4_web.pdf

AMCUC study

ELU-4-54A576-1

AMCUC study

APPROACH longitudinal study

df77529e-c79d-11ec-9b1d-acde48001122